HUMA
Humacyte, Inc.
Biotechnology
Market Cap$140M
5Y Perf.-89.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HUMA vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-90.3%
HUMA vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HUMA | NVCR |
|---|---|---|
| Industry | Biotechnology | Medical - Instruments & Supplies |
| Market Cap | $140M | $1.92B |
| Revenue (TTM) | $9M | $674M |
| Net Income (TTM) | $-37M | $-173M |
| Gross Margin | 9.9% | 75.2% |
| Operating Margin | -12.0% | -27.2% |
| Total Debt | $17M | $290M |
| Cash & Equiv. | $45M | $103M |
HUMA vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HUMA
NVCR
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Humacyte, Inc. (HUMA) | 100 | 10.6 | -89.4% |
| NovoCure Limited (NVCR) | 100 | 9.7 | -90.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HUMA vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVCR leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Humacyte, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
HUMA
Humacyte, Inc.
The Growth Leader
HUMA is the clearest fit if your priority is growth.
- 79.5% revenue growth vs NVCR's 8.3%
Best for: growth
NVCR
NovoCure Limited
The Income Pick
NVCR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 2.20
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 30.3% 10Y total return vs HUMA's -88.8%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HUMA | 79.5% revenue growth vs NVCR's 8.3% |
| Quality / Margins | NVCR | -25.7% margin vs HUMA's -420.2% |
| Stability / Safety | NVCR | Beta 2.20 vs HUMA's 3.27 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVCR | +1.1% vs HUMA's -11.5% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs HUMA's -40.4% |
HUMA vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVCRLAGGINGHUMA
HUMAHumacyte, Inc.
0leads
NVCRNovoCure Limited
4leads
6 Total Categories
CATEGORYLEADERvs HUMAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NVCR4/5
Valuation MetricsMultiples, price ratios, and targets
NVCR1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
NVCR5/6
Risk & VolatilityBeta, volatility, and downside exposure
NVCR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NVCR leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 76.6x HUMA's $9M. Profitability is closely matched — net margins range from -25.7% (NVCR) to -4.2% (HUMA).
| Metric | HUMAHumacyte, Inc. | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $9M | $674M |
| EBITDAEarnings before interest/tax | -$98M | -$165M |
| Net IncomeAfter-tax profit | -$37M | -$173M |
| Free Cash FlowCash after capex | -$106M | -$48M |
| Gross MarginGross profit ÷ Revenue | +9.9% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -12.0% | -27.2% |
| Net MarginNet income ÷ Revenue | -4.2% | -25.7% |
| FCF MarginFCF ÷ Revenue | -12.1% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +66.7% | -100.0% |
NVCR leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
NVCR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | HUMAHumacyte, Inc. | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $140M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $112M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.86x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.92x |
| Price / BookPrice ÷ Book value/share | — | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
NVCR leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — HUMA and NVCR each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs HUMA's 2/9, reflecting solid financial health.
| Metric | HUMAHumacyte, Inc. | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | — | -50.8% |
| ROA (TTM)Return on assets | -40.4% | -16.5% |
| ROICReturn on invested capital | — | -16.4% |
| ROCEReturn on capital employed | -100.5% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | — | 0.85x |
| Net DebtTotal debt minus cash | -$28M | $187M |
| Cash & Equiv.Liquid assets | $45M | $103M |
| Total DebtShort + long-term debt | $17M | $290M |
| Interest CoverageEBIT ÷ Interest expense | -2.47x | -96.80x |
Evenly matched — HUMA and NVCR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
NVCR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HUMA five years ago would be worth $1,080 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, NVCR leads with a +1.1% total return vs HUMA's -11.5%. The 3-year compound annual growth rate (CAGR) favors NVCR at -37.6% vs HUMA's -39.9% — a key indicator of consistent wealth creation.
| Metric | HUMAHumacyte, Inc. | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | +10.8% | +28.3% |
| 1-Year ReturnPast 12 months | -11.5% | +1.1% |
| 3-Year ReturnCumulative with dividends | -78.3% | -75.7% |
| 5-Year ReturnCumulative with dividends | -89.2% | -91.3% |
| 10-Year ReturnCumulative with dividends | -88.8% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -39.9% | -37.6% |
NVCR leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
NVCR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVCR is the less volatile stock with a 2.20 beta — it tends to amplify market swings less than HUMA's 3.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs HUMA's 36.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HUMAHumacyte, Inc. | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.27x | 2.20x |
| 52-Week HighHighest price in past year | $2.93 | $20.06 |
| 52-Week LowLowest price in past year | $0.55 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +36.9% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 65.9 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 6.7M | 1.5M |
NVCR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HUMA as "Buy" and NVCR as "Buy". Consensus price targets imply 177.8% upside for HUMA (target: $3) vs 99.0% for NVCR (target: $34).
| Metric | HUMAHumacyte, Inc. | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $3.00 | $33.50 |
| # AnalystsCovering analysts | 11 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVCR leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallNovoCure Limited (NVCR)Leads 4 of 6 categories
Loading custom metrics...
HUMA vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is HUMA or NVCR a better buy right now?
Analysts rate Humacyte, Inc.
(HUMA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HUMA or NVCR?
Over the past 5 years, Humacyte, Inc.
(HUMA) delivered a total return of -89. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus HUMA's -88. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HUMA or NVCR?
By beta (market sensitivity over 5 years), NovoCure Limited (NVCR) is the lower-risk stock at 2.
20β versus Humacyte, Inc. 's 3. 27β — meaning HUMA is approximately 48% more volatile than NVCR relative to the S&P 500.
04Which is growing faster — HUMA or NVCR?
On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21.
8% year-over-year, compared to -17. 8% for Humacyte, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HUMA or NVCR?
NovoCure Limited (NVCR) is the more profitable company, earning -20.
8% net margin versus -420. 2% for Humacyte, Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -1197. 7% for HUMA. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — HUMA or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is HUMA or NVCR better for a retirement portfolio?
For long-horizon retirement investors, NovoCure Limited (NVCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Humacyte, Inc. (HUMA) carries a higher beta of 3. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVCR: +30. 3%, HUMA: -88. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HUMA and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.